Helius Medical Technologies Inc HSDT

Healthcare Medical Devices

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

NDAQ:HSDT - Post by User

Helius Medical Technologies Inc

Bullboard Posts

Post by miningfundion Jan 29, 2019 3:25pm

136 Views

Post# 29292752

Information for FDA - why the timing?

Management: “We believe we have the data and information to address FDA’s questions”.

Prokofiev: I had posted last week that I expect Helius to resubmit its data in the next 2-5 weeks, but I believe pushing this out by a week to be more realistic. Therefore, my new estimate is 3-6 weeks.

If management has the data and information, why should it take 3-6 weeks to get it to the FDA?

Bullboard Posts

Air Canada stock rises as service from Ottawa grows